Original Research Article

The efficacy of intrallesional triamcinolone acetonide (20mg/ml) in the treatment of keloid

Adit M. Garg1, Yogesh M. Shah1, Alok Garg2, Shazia Zaidi1, Kshitij Saxena1*, Khushboo Gupta1, Ramya B. G.1

1Department of DVL, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India
2Consultant Plastic Surgeon, Alok Hospital, Talwandi, Kota, Rajasthan, India

Received: 28 January 2018
Accepted: 02 February 2018

*Correspondence:
Dr. Kshitij Saxena,
E-mail: drkshitjsaxena@live.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Management of keloid is difficult as well as challenging. Intrallesional triamcinolone acetonide (TAC) injections have remained a gold standard in non-surgical management of keloid. TAC is generally used in the concentration of 40mg/ml, which causes adverse effects such as local dermal atrophy and hypopigmentation. Aim was to study efficacy and adverse effects of TAC in treatment of keloid, in a lesser concentration of 20mg/ml.

Methods: An open label study was conducted from November 2015 to May 2017 on 25 subjects of either gender, in the age group 11-55 years, at a medical college hospital. Intrallesional injection TAC 20 was administered in the keloid at an interval of 3 weeks, for a total of 6 sessions, over a period of 18 weeks. Vancouver scar scale (VSS) was used to assess the improvement and SPSS 21 for statistical analysis.

Results: Mean age of keloid subjects was 30.72 years and median duration of keloid was 8 months. The mean VSS score before treatment was 8.36 which reduced to 3.20 after treatment. Mean percentage change in VSS score was 62.79%, which was very highly significant (p <0.001). Physician’s assessment was ‘Very Good’ in 52.0% and ‘Excellent’ in 5 (20%). Adverse effect of atrophy was seen in 3 (12%), hypopigmentation in 11 (44%) and telangiectasia in 4 (16%).

Conclusions: Intrallesional injection triamcinolone acetonide 20mg/ml gives very good to excellent improvement in the majority of patients of keloid. Local adverse effects seen were hypopigmentation, atrophy and telangiectasia.

Keywords: Adverse effects, Efficacy, Keloid, Triamcinolone (20mg/ml), Vancouver scar scale

INTRODUCTION

Keloids are characterized by firm, mildly tender, bosselated nodules or plaques occurring more frequently on shoulders, chest, neck, upper arms and face.1 They are benign overgrowth of fibrous tissue that usually develops after healing of a skin injury and extends beyond the original defect.2 The uncontrolled growth of keloid continues progressively, and the patients experience itch and pain. The fibrous keloid progresses to gain a larger size, leads to cosmetic disfigurement, functional impairment, and affects the quality of life adversely.3

It is supposed that corticosteroids owing to their anti-inflammatory properties are helpful in suppressing hypertrophic scars and the keloid.5 The corticosteroids diminish collagen and glycosaminoglycan synthesis, inhibit fibroblast growth and enhance collagen and fibroblast degeneration.5,6
Triamcinolone acetonide (TAC) is the most commonly used intralesional corticosteroid for the treatment of keloids and is considered to be the first line therapy for the treatment of keloids. TAC is used in different concentrations ranging from 10 to 40mg/ml. Different studies recommend different intervals between successive injections and the number of injections may vary from four to eight.

Intralesional injection TAC 40mg/ml is more commonly used, as the concentration of 40mg/ml is very effective in controlling keloid. However, local side effects such as dermal atrophy, telangiectasia, hypopigmentation and pain at the site of injection due to TAC 40mg/ml are common. Pain can be avoided by use of topical anesthesia and/or regional injections of local anesthetic around the scars. Hypopigmentation is not a problem in non-pigmented western skin but is significant in pigmented skin.

Aim was to study the efficacy and the adverse effect of intralesional injection triamcinolone acetonide in treatment of keloid, in concentration of 20mg/ml.

**METHODS**

The study was carried out on 25 patients in Dermatology OPD of a medical college hospital in North India from November 2015 to May 2017 (one year and six months). Patients of keloid of either gender, in the age group 11 to 55 years, were included in the study. Patients with local infection, immune-compromise, pregnancy or lactation and those who had received treatment for keloid during previous 6 months were excluded. Sample size was calculated on the basis of decrease in volume of the keloid.

Injection Triamcinolone acetonide 20mg/ml (TAC 20) was injected intralesionally at an interval of 3 weeks, for a total of 6 sittings over a period of 18 weeks. Injection Triamcinolone acetonide 40mg/ml was diluted using lignocaine with adrenaline, in equal proportions, to get a final concentration of 20mg/ml. The lesion was infiltrated with the drug suspension, using a disposable insulin syringe and 26-gauge needle, till complete and uniform blanching of the lesion, was achieved. The subject was not administered any sedation or analgesia prior to the injection.

The details of the subject including the Fitzpatrick skin type, duration, site, number and parameters such as height, pliability, pigmentation and height are assessed, in order to determine the score. The score allotted for pliability is from 0 to 5, score for height and vascularity from 0 to 3 and for pigmentation from 0 to 2, to give a maximum possible score of 13. The decreasing mean value of the total score indicates clinical improvement, in the scar.

Scar height was measured with calipers, and scar pliability assessed by palpation; scar vascularity rated by visual inspection, and the rate of refill, after blanching it. Blanching was achieved by a transparent plastic sheet with VSS score sheet, pasted on it. Scar pigmentation was assessed after blanching and comparing the scar color with the surrounding skin. The percentage reduction in VSS was graded according to the Quartile score with ≤25% reduction in VSS graded as Poor, 26-50% reduction as Good, 51-75% reduction Very good and >75% reduction as Excellent response.

Data was analyzed using Statistical Package for Social Sciences (SPSS) version 21.0. Wilcoxon signed rank was used to assess the outcome and ‘p’ value less than 0.05 was considered to be a statistically significant change.

**RESULTS**

A total of 25 subjects of keloid of either gender, were treated with intralesional injection of triamcinolone acetonide 20mg/ml (TAC-20). All the 25 subjects completed the study. Male were 52%, female 48% and the mean age was 31.76±13.08 years. Family history of keloids was present in 4 (16.0%). The majority (60.0%) of the subjects had Fitzpatrick Skin type IV. Duration of keloid ranged from 1 to 36 months with a median duration of 7 months.

| Table 1: Demographic data. |
|---------------------------|
| Keloid patients | Value |
| **Gender** |  |  |
| Male | 13 (52%) |  |
| Female | 12 (48%) |  |
| **Age (year)** | Mean 31.76±13.08 |  |
| **Family history** |  |  |
| Positive | 4 (16.0%) |  |
| Negative | 21 (84%) |  |
| **Skin Photo-type** |  |  |
| Type IV | 15 (60.0%) |  |
| Type V | 10 (40.0%) |  |
| **Duration (months)** | Median 7 |  |

The majority (92%) had one or two keloids and 2 (8%) of the subjects had more than three keloids.

| Table 2: Number of keloids. |
|-----------------------------|
| Patients | Number of Keloids |
| 18 (72%) | 1 |  |
| 5 (20%) | 2 |  |
| 0 (0%) | 3 |  |
| 1 (4%) | 4 |  |
| 1 (4%) | 5 |  |
The majority (90%) of keloids were either on the chest or shoulders.

**Table 3: Location of keloids.**

| Location on the body | No. of keloids (30) |
|----------------------|---------------------|
| Chest                | 16 (52 %)           |
| Shoulder and arm     | 11 (38 %)           |
| Face and ear         | 3 (10 %)            |
| Back                 | 0 (%)               |
| Thigh and leg        | 0 (%)               |

An assessment of Vancouver Scar Scale (VSS) score was carried out at the baseline i.e. before the treatment, and at 3 weeks after the last (sixth) injection, i.e. at 18 weeks from the first injection: Before starting the treatment, at the baseline, mean VSS score was 8.36±1.60 (Median 8.0), which reduced to 3.20±1.92 (Median 3.00) at final follow up, thus showing a mean change of -5.16±1.63 (62.79%). On evaluating the data, it was found to be statistically significant (p<0.001).

**Table 4: VSS score following treatment with intralesional injection of triamcinolone acetonide.**

| VSS score (n=25) | Median | Mean | SD |
|------------------|--------|------|----|
| At baseline      | 8.00   | 8.36 | 1.60 |
| 4.5 months (final follow up) | 3.00 | 3.20 | 1.92 |

Mean±SD -5.16±1.63 % change -62.79%; z=4.401; p<0.001

**Figure 1: Pretreatment photograph of keloid on back of shoulder.**

Physician rated outcome was ‘Very good’ to ‘Excellent’ in 18 (72%) and ‘Good’ in 5 (20%) subjects. There were 2 (8%) cases in which outcome was evaluated as ‘Poor’.

**Table 5: Physician rated outcome.**

| Assessment       | n = 25 |
|------------------|--------|
| Poor             | 2 (8%) |
| Good             | 5 (20%)|
| Very good        | 13 (52%)|
| Excellent        | 5 (20%)|

**Figure 2: Post-treatment photograph after TAC-20 (excellent response).**

**Figure 3: Pretreatment photograph of keloid.**

**Figure 4: Post-treatment photograph of keloid after TAC20 (very good response but with atrophy and telangiectasia).**

Pain was the most common adverse effect as reported by 21 (84%) patients. Hypopigmentation was observed in 11 (44%), telangiectasia in 4 (16%), and dermal atrophy in 3 (12%) of the subjects (Table 6).
Table 6: Adverse effects.

| Adverse Effects   | n = 25 |
|-------------------|--------|
| Pain              | 21(84%)|
| Hypopigmentation  | 11(44%)|
| Telangiectasia    | 4 (16%)|
| Dermal atrophy    | 3 (12%)|

**DISCUSSION**

Pathogenesis of the keloid is still not well understood. A variety of treatment modalities such as silicone gel sheeting, intralesional injections, cryotherapy, surgical manipulation, laser and radiotherapy are used, but no particular treatment is suitable or effective in all cases and keloid it tends to recur, irrespective of the treatment used. Drugs like bleomycin, interferon, 5-fluorouracil when used intralesionally, have a better efficacy, but are costly and cause severe drug reactions. Surgery and laser therapy have limitations and radiotherapy causes malignancy.

Corticosteroids seem to be effective as they diminish collagen and glycosaminoglycan synthesis, inhibit fibroblast growth, enhance collagen and fibroblast degeneration and have powerful anti-inflammatory effect. The anti-inflammatory effect of TAC in addition to inhibition of collagen and glycosaminoglycan synthesis, and degeneration of fibroblast/collagen might be giving it an edge, however the drug causes local adverse effects such as dermal atrophy, telangiectasia and hypopigmentation in large number of patients.

Inability to measure amount of drug used with respect to area as well as thickness of keloid, has been a major limitation in this study as in most other studies. Consequently, complete blanching of the keloid, was considered to be the end point, for the dose of the drug injected intralesionally.

TAC is cost effective and practical and has become first-line treatment for keloid, in spite of many limitations. Studies have reported that lower dose of TAC, i.e. 20mg/ml reduces the side effects of TAC without jeopardizing the efficacy.

In this study, majority of the subjects were in the age group <30 years; males being slightly more than females. Uzair et al and Ahuja et al also observed predominance of keloid in the younger age group. The duration of keloids in majority of subjects was less than 12 months. The majority showed a very good to excellent response conforming observations from studies. The Keloid were found to be most common on the chest (60%), followed by shoulder (20%), arm (18%) and face (10%) similar to observations.

In the present study following intralesional TAC 20, a majority (62.79%) of patients of keloids showed significant mean reduction in VSS. The observations were in conformity with that of Uzair et al. The improvement observed was comparable to TAC 40mg/ml used by Chatterjee A and Shanthi M et al. The improvement in keloid with TAC 20 mg/ml was observed to be similar to TAC 40mg/ml used in other studies.

Immediate pain at the site of injection was the commonest side effect with TAC 20 as reported by 84% of the subjects. However, the pain was mild, transitory and resolved within few hours, which is attributed to dilution with lignocaine and adrenaline which causes a sustained hypothesia and therapeutic effect at the site, locally. Hypopigmentation was observed in 44%, atrophy in 12% and telangiectasia in 16% of the subjects treated by TAC 20; this was comparable to other studies. Manuskiatti et al and Jamnati et al using TAC-20, reported hypopigmentation in 20%, atrophy in 10% and telangiectasia in 20% of patients. Bilal et al using TAC 40mg/ml reported hypopigmentation (29%), atrophy (4%) and telangiectasia (25%). An occurrence of atrophy in 18% of cases was from studies.

In the present study with TAC 20, hypopigmentation was observed in 44 % of the subjects. The incidence of hypopigmentation in the study was much higher as compared to other studies probably because all subjects in this study, were of Fitzpatrick skin type IV and V. Most other studies do not mention the skin prototype of the subjects.

Limitations of the study includes therapeutic effect of injection TAC was studied over a period of only 18 weeks for a patient, which may be inadequate. Post treatment follow up of patient should be of a longer period to judge the recurrence.

**CONCLUSION**

TAC 20mg/ml gives very good to excellent response in a majority of patients and the improvement is comparable to the result with TAC 40mg/ml as reported by other workers. TAC 20 also causes adverse effects such as hypopigmentation, telangiectasia and atrophy. However adverse effects with TAC 20 are less compared to TAC 40. Immediate postoperative pain occurs but is mild and transitory.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Lee SS, Yosipovitch G, Chan YH, Goh CL. Pruritus, pain, and small nerve fiber function in keloids: a controlled study. J Am Acad Dermatol. 2004;51:1002-6.
2. Burrows NP, Lovell CR. Disorders of Connective Tissue. In: Burns T, Rook A. Rooks textbook of dermatology. 8th Ed. Oxford: Wiley-Blackwell; 2010:45-45.56.

3. Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol. 2007;25:26-32.

4. Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg. 2008;206:719-30.

5. Cruz NI, Korchin L. Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg. 1994;33:401-5.

6. Boyadijiev C, Popchristova E, Mazzaglova J. Histomorphologic changes in keloids treated with Kenacort. J Trauma. 1995;38:299-302.

7. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560-71.

8. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Molecular Medicine. 2011;17(1-2):113-25.

9. Tredget EE, Nedelee B, Scott PG, Ghahary A. Hypertrophic scars, keloids, and contractures: the cellular and molecular basis for therapy, Surg Clin North Am. 1997;77:701-30.

10. Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol. 2008;47(2):183-6.

11. Nedelee B, Shankowsky HA, Tredget EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil. 2000;21:205-12.

12. Li-Tsang CWP, Lau JCM, Liu SKY. Validation of an objective scar pigmentation measurement by using a spectrophotometer. Burns. 2003;29:779-84.

13. Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. J Burn Care Rehabil. 1995;16:535-8.

14. Ogawa R, Chin MS. Animal models of keloids and hypertrophic scars. J Burn Care Res. 2008;29:1016-7.

15. Shanith FM, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian JDVL. 2008;74(4):343-8.

16. Carvalhaes SM, Petroianu A, Ferreira MAT, Barros VMD, Lopes RV. Assessment of the treatment of earlobe keloids with triamcinolone injections, surgical resection, and local pressure. Revista do Colélio Brasileiro de Cirurgiões. 2015;42(1):9-13.

17. Gupta S, Sharma V. Standard guidelines of care: Keloids and hypertrophic scars. Indian JDVL. 2011;77(1):94.

18. Wong TS, Li JZH, Chen S, Chan JYW, Gao W. The Efficacy of Triamcinolone Acetonide in Keloid Treatment: A Systematic Review and Meta-analysis. Front Med. 2016;3:71.

19. Uzair M, Butt G, Khurshid K, Pal S. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Our Dermatol Online. 2015;6(3):280-4.

20. Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns. 2014;40(4):583-8.

21. Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast Surg. 2007;31:468-94.

22. Juckett G, Hartmann-Adams H. Management of Keloids and Hypertrophic Scars. Am Fam Physician. 2009 Aug 1;80(3):253-60.

23. Jannati P, Aref S, Jannati AA, Jannati F, Moravvej H. Comparison of Therapeutic Response of Keloids to Cryotherapy Plus Intralesional Triamcinolone Acetonide or Verapamil Hydrochloride. J Skin Stem Cell. 2015;2(1):e29284:7-12.

24. Danielsen PL, Rea SM, Wood FM, Fear MW, Viola HM, Hool LC, et al. Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Controlled Trial. Acta Derm Venereol. 2016;96;774-8.

25. Martin MS, Collawn SS. Combination treatment of CO2 fractional laser, pulsed dye laser, and triamcinolone acetonide injection for refractory keloid scars on the upper back. J Cosmetic Laser Therap. 2013;15(3):166-70.

26. Sanders KW, Gage-White L, Stucker FJ. Topical mitomycin C in the prevention of keloid scar recurrence. Arch Facial Plast Surg. 2005;7:172-5.

27. Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician. 2009;80:253-60.

28. Manuskiatti W, Fitzpatrick RE. Treatment response of keloids and hypertrophic sternotomy scars. Arch Dermatol. 2002;138:1149-55.

29. Bilal M, Tahmeedullah, Irфанullah, Shah SA. Clinical outcome of intralesional corticosteroid versus intralesional Verapamil in the treatment of post burn Keloid scars of the head and neck region. Pak J Surg. 2013;29(4):263-8.

Cite this article as: Garg AM, Shah YM, Garg A, Zaidi S, Saxena K, Gupta K, Ramya BG. The efficacy of intralesional triamcinolone acetonide (20mg/ml) in the treatment of keloid. Int Surg J 2018;5:868-72.